About PhytoPharma Nexus

PhytoPharma Nexus is an international scientific platform dedicated to fostering knowledge exchange, research communication, and innovation across the fields of pharmaceutical sciences, biotechnology, phytomedicine, bioinformatics, nanotechnology, and translational healthcare research.

Established under the vision of promoting evidence-based science and interdisciplinary collaboration, PhytoPharma Nexus serves as a forum for researchers, academicians, healthcare professionals, industry experts, and students to share emerging discoveries, scientific perspectives, scholarly articles, reviews, technical insights, and research-driven innovations.

The platform is designed to facilitate the dissemination of scientific knowledge through publications, thematic issues, scientific communications, educational content, workshops, conferences, and collaborative initiatives that bridge fundamental research with real-world healthcare applications.

By connecting traditional wisdom with modern scientific advancements, PhytoPharma Nexus aims to create a dynamic ecosystem that supports learning, innovation, and the advancement of biomedical and pharmaceutical research for the benefit of the global scientific community.

Focus Area:

Drug Discovery & Development
Phytomedicine & Natural Products
Biotechnology & Molecular Biology
Pharmaceutical Sciences
Bioinformatics & Computational Biology
Nanotechnology & Nanomedicine
Precision Medicine
Artificial Intelligence in Healthcare

Connecting Research, Innovations and Scientific Excellence for a Better Tomorrow

〰️

Connecting Research, Innovations and Scientific Excellence for a Better Tomorrow 〰️

Advancing Translational Oncology Through Nanomedicine, Phytochemicals and AI

Professor Eyad Elkord, PhD, MPhil, BSc

The future of cancer research depends on the questions we ask today, and the discoveries we choose to pursue tomorrow.

Can nanomedicine unlock the therapeutic potential of phytochemicals? Can AI accelerate the journey from natural compounds to targeted cancer therapies? And what will it take to transform promising laboratory findings into meaningful clinical advances?

Join PhytoPharma Nexus in exploring these questions through insights from Professor Eyad Elkord, a leading voice in oncology and immunology, in conversation with Dr. Sumit Sheoran.

Your perspective matters. Which emerging approach do you believe holds the greatest promise for the future of cancer therapeutics, nanomedicine, phytochemical-based interventions, AI-driven drug discovery, or their integration?

Follow PhytoPharma Nexus for more expert insights, scientific perspectives, and conversations at the frontiers of pharmaceutical and biomedical innovation.

About the Interviewee

Professor Eyad Elkord, PhD, MPhil, BSc, is the Director of the Centre of Excellence for Oncology and Immunology at the Department of Biosciences and Bioinformatics, School of Science, Xi’an Jiaotong-Liverpool University, Suzhou, China. His academic profile reflects a focus on oncology and immunology, with perspectives spanning cancer immunotherapy, tumour biology, and translational biomedical research.

Through this interview, Professor Elkord shares insights into emerging therapeutic strategies, the potential of plant-derived bioactive compounds, and the role of artificial intelligence and nanomedicine in advancing cancer research.

Contact: eyad.elkord@xjtlu.edu.cn

Download Full Interview (PDF)

Explore Professor Eyad Elkord’s perspectives on these emerging frontiers of cancer research through the five questions below.

Q1. In the current era of targeted therapies, how do you envision the integration of advanced nanoformulations and translational phytomedicine modifying the tumor microenvironment and overcoming drug resistance in oncology?

The tumor microenvironment (TME) is increasingly recognized as a central determinant of treatment response and therapeutic resistance. Beyond genetic alterations in tumor cells, interactions among immune populations, stromal cells, metabolic regulators, and inflammatory mediators critically influence cancer progression and clinical outcomes.
Advanced nanoformulations offer an opportunity to improve the therapeutic application of phytocompounds through enhanced stability, targeted delivery, optimized bioavailability, and controlled release. Such approaches may increase intratumoral drug accumulation while reducing systemic toxicity. Additionally, translational phytomedicine may contribute to remodeling immune and inflammatory signaling pathways within the TME.
Emerging evidence suggests that integrating nanomedicine with biologically active natural compounds may support more precise modulation of the tumor ecosystem and potentially mitigate mechanisms associated with treatment resistance. Nevertheless, future success will depend on rigorous mechanistic studies, reproducible formulation platforms, and robust clinical validation.

Q2. From your extensive expertise, do you see a potential for plant-derived bioactive compounds to act as synergistic adjuvants alongside modern immune checkpoint inhibitors?

There is growing scientific interest in understanding whether plant-derived bioactive compounds can enhance antitumor immunity and complement current immunotherapeutic approaches. Certain phytochemicals have demonstrated immunomodulatory effects through regulation of inflammatory signaling, immune-cell activation, oxidative stress responses, and interactions within the tumor microenvironment.
From a translational perspective, selected compounds may act as supportive adjuvants capable of enhancing immune responsiveness and reducing local immunosuppressive conditions. However, the complexity of immune regulation requires careful interpretation of preclinical findings and emphasizes the importance of biomarker-guided strategies and clinical validation.
Future progress in this area should focus on evidence-based integration rather than empirical combination approaches.

Q3. How significantly are modern AI and Computational Drug Discovery tools accelerating the screening of natural products for target-specific cancer therapeutics?

Artificial intelligence (AI), machine learning (ML), and computer-aided drug discovery (CADD) are increasingly transforming oncology research and therapeutic development. These technologies accelerate target identification, virtual screening, molecular interaction prediction, lead optimization, and toxicity assessment.
Within natural product research, AI-supported pipelines allow investigators to navigate highly complex chemical spaces more efficiently and prioritize compounds with greater therapeutic potential before experimental validation.
Importantly, computational approaches should complement—not replace—experimental and translational research, serving as tools that enhance precision, speed, and decision-making throughout the drug development process.

Q4. What is your advice for global researchers working on herbal therapeutics to ensure stringent reproducibility and chemical standardization that meets rigorous global regulatory guidelines?

One of the most important barriers to the successful translation of herbal therapeutics is achieving reproducibility and standardization across studies and production systems.
Researchers should prioritize comprehensive phytochemical characterization, standardized extraction and processing protocols, batch-to-batch consistency, transparent methodological reporting, mechanistic validation, and alignment with internationally recognized quality and regulatory frameworks.
Importantly, the therapeutic potential of natural products should be evaluated under the same scientific rigor applied to conventional pharmaceutical development.
Strengthening these principles will improve reproducibility, increase regulatory confidence, and accelerate clinical translation.

Q5. As an elite mentor, what is your key advice for young Ph.D. scholars and faculty members who wish to transition their benchside oncology research into industry-ready clinical innovations or biotech startups?

My advice is to adopt a translational mindset early in the research journey.
Young scientists should continuously ask not only whether their work is scientifically novel, but whether it addresses a meaningful clinical need and possesses realistic potential for implementation. Building multidisciplinary collaborations across academia, medicine, engineering, and industry has become increasingly essential.
Beyond scientific excellence, developing skills in communication, intellectual property, regulatory science, project management, and entrepreneurship will strengthen the pathway from discovery to patient impact.
Ultimately, the success of oncology research should be measured not only by publications but also by its ability to generate meaningful improvements in patient care and public health.

Call For Paper

Accepting:

Original Research Articles
Review Articles
Short Communications
Scientific Letters
Case Studies
Perspectives & Commentary

PhytoPharma Nexus invites researchers, acdemicians, scientists, industry professionals and students to contribute their valuable research and innovations

Publication Frequency

Monthly (12 issue Per Year)

Submit Manuscript

Published Manuscripts

Nanocarriers at the Crossroads: Advances, Mechanisms, and Translational Frontiers in Drug Delivery

Article Type: Mini Review

Author: Hritik Kumar

Affiliation: Department of Biotechnology, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305817, Rajasthan, India.

Corresponding Author: Hritik Kumar
Email: hritikkumardeeg@gmail.com

Abstract

Nanomedicine has revolutionized drug delivery due to its ability to offer spatial and temporal control of the released drug. The development of drug delivery systems using nanocarriers such as liposomes, polymers, lipid nanoparticles (LNPs), dendrimers, and inorganic nanoparticles has evolved from mere concept to practice in the last 20 years. In this mini-review, we compile existing information regarding the principles of designing nanocarriers for drug delivery, targeting strategies (both active and passive), “smart” nanoplatforms which respond to stimuli, and the significant contribution of LNPs in nucleic acid therapies. We discuss some of the key obstacles to successful translation, like protein corona effect, heterogeneity in enhanced permeation and retention effect, and production scaling problems, along with potential solutions like biomimetic approaches, AI optimization, and organoids derived from patients.

Keywords

Nanomedicine; drug delivery systems; nanoparticles; stimuli-responsive nanocarriers; lipid nanoparticles; tumor microenvironment; EPR effect; clinical translation

Read/Download Manuscript (PDF)

Editorial Board

Prof. Dr. Hemanthkumar Manikyam,
Vice President Research And Development,
Botanic Healthcare , Hyderabad, Telangana, India

Dr. Ghanshyam R. Parmar,
Professor and Head,
Department of Pharmacy,
Sumandeep Vidyapeeth, Vadodara, Gujrat, India

Dr. S. Shobana,
Assistant Professor,
Department of Biotechnology,
Vel Tech Rangarajan Dr Sagunthala R&D Institute of Science and Technology, Chennai,Tamil Nadu, India

Dr. Ravi Kant,
Associate Professor,
Department of Zoology,
CCSHAU, Hisar, Haryana, India

Many More Eminent Scientists and Researchers Joining Soon

Why Publish With Us?

✔ International Visibility

✔ Rapid Editorial Processing

✔ Expert Peer Review

✔ Multidisciplinary Scope

✔ Open Scientific Exchange

✔ Research Networking Opportunities